Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


19 Items
Title  Creator  Group name  Publishing year 
Lung Cancer in France Pujol et al. EquipeMY 2021-01
Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design Garrido et al. EquipeAM 2021-04
Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study Pujol et al. EquipeAM 2021-11
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma Bousquet Mur et al. EquipeAM 2020-02-03
Is Darbepoietin Alfa Linked to Mortality During Non-Small Cell Lung Cancer Chemotherapy? Pujol and Roch EquipeMY 2020-02
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma Nokin et al. EquipeAM 2020-08-06
Development and Validation of a Simplified Prognostic Score in SCLC Negre et al. EquipeMY 2020-03
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab Herbreteau et al. EquipeAM 2020-11-27
Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors Roch et al. EquipeMY 2020-05
Ultra-sensitive EGFRT790Mdetection as an independent prognostic marker for lung cancer patients harboring EGFRdel19mutations and treated with first-generation TKIs Vendrell et al. EquipePC Apr 01, 2019
An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer Pujol et al. EquipeMY 2019
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial Pujol et al. EquipeAM May 2019
Synchronous multiple non-small cell lung cancers in an allograft lung recipient Pujol et al. EquipeAM Oct 2018
Introduction to the Special Section: The Experience and Impact of Lung Cancer Stigma Hamann and Pujol EquipeAM 08 2018
Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer Middleton et al. EquipeAM May 2018
Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies Langer et al. EquipeAM 09 2017
Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches Vendrell et al. EquipePC 10 02, 2017
Lung Cancer Screening with Chest Computed Tomography in People Living with HIV: A Review by the Multidisciplinary CANCERVIH Working Group Makinson et al. EquipeAM 10 2016
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial Vansteenkiste et al. EquipeAM Jun 2016
19 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés